

Supplementary Table S1. The numbers of OS, BCSS and DFS events in the investigated breast cancer subgroups

	Number of patients	OS event* n (%)	BCSS event** n (%)	DFS event*** n (%)	Median follow- up time years (range)
All	278	98 (35)	68 (24)	91 (33)	13.1 (0.4-18.8)
CD163+ high	75	41 (55)	33 (44)	37 (49)	
CD163+ low	201	56 (28)	34 (17)	53 (26)	
CD68+ high	60	26 (43)	22 (37)	27 (45)	
CD68+ low	210	67 (32)	43 (20)	61 (29)	
HER2+	139	55 (40)	43 (31)	53 (38)	12.7 (0.4-18.3)
CD163+ high	42	27 (64)	24 (57)	26 (62)	
CD163+ low	96	27 (28)	18 (19)	26 (27)	
CD68+ high	90	41 (46)	32 (36)	36 (40)	
CD68+ low	46	11 (24)	8 (17)	14 (30)	
HER2+/HR+	82	28 (34)	23 (28)	28 (34)	13.0 (0.4-18.3)
CD163+ high	31	16 (52)	15 (48)	16 (52)	
CD163+ low	50	11 (22)	7 (14)	11 (22)	
CD68+ high	47	19 (40)	16 (34)	18 (38)	
CD68+ low	33	7 (21)	5 (15)	8 (24)	
HER2+/HR-	57	27 (47)	20 (35)	25 (44)	11.6 (0.7-18.3)
CD163+ high	17	13 (76)	11 (65)	12 (71)	
CD163+ low	40	14 (35)	9 (23)	13 (33)	
CD68+ high	37	19 (51)	15 (41)	17 (46)	
CD68+ low	19	7 (37)	4 (21)	7 (37)	
HER2-	139	43 (31)	25 (18)	38 (27)	13.5 (0.9-18.8)
CD163+ high	37	16 (43)	10 (27)	13 (35)	
CD163+ low	101	27 (27)	15 (15)	25 (25)	
CD68+ high	19	8 (42)	7 (37)	10 (53)	
CD68+ low	115	33 (29)	18 (16)	28 (24)	
HER2-/HR+	121	37 (31)	21 (17)	34 (28)	13.6 (2.1-18.8)
CD163+ high	27	11 (41)	7 (26)	10 (37)	
CD163+ low	94	26 (28)	14 (15)	24 (26)	
CD68+ high	42	9 (21)	5 (12)	13 (31)	
CD68+ low	75	26 (35)	16 (21)	21 (28)	
HER2-/HR-	17	6 (35)	4 (24)	4 (24)	12.9 (0.9-18.4)
CD163+ high	10	5 (50)	3 (30)	3 (30)	
CD163+ low	7	1 (14)	1 (14)	1 (14)	
CD68+ high	7	3 (43)	3 (43)	3 (43)	
CD68+ low	10	3 (30)	1 (10)	1 (10)	

OS, overall survival; BCSS, breast cancer-specific survival; DFS disease-free survival; HR+, hormone receptor positive; HR-, hormone receptor negative

*OS event=death; **BCSS event=breast cancer death; ***DFS event=disease recurrence